Fortis Healthcare: Rebuilding Brand Trust After Promoter Fraud

Executive Summary

Between 2018 and 2024, Fortis Healthcare executed one of the most consequential corporate and brand turnarounds in the history of Indian private healthcare. The collapse of its founding promoters — the Singh brothers — under allegations of large-scale financial fraud triggered an acute crisis of institutional trust. The subsequent strategy of stabilisation under Malaysian healthcare giant IHH Healthcare, led operationally by MD & CEO Dr. Ashutosh Raghuvanshi, combined governance reform, clinical repositioning, digital transformation, and portfolio rationalisation to rebuild Fortis as a credible, patient-centric, professionally managed healthcare brand. This case examines those strategic choices as a model of trust recovery in a high-stakes, high-credence service industry.

Industry & Competitive Context

India's private hospital sector is a high-growth, structurally complex industry characterised by significant information asymmetry between providers and patients. Healthcare is a credence good — patients are largely unable to evaluate the quality of the service independently, making institutional trust, clinical accreditation, and brand reputation central to patient acquisition and retention. In this context, brand equity is not merely a marketing variable; it is a functional prerequisite for occupancy and revenue. By 2018, the top four private hospital chains — Apollo Hospitals, Max Healthcare, Narayana Health, and Fortis Healthcare — had collectively established themselves as the dominant players in tertiary and quaternary care across major Indian metros. Competition was intense along multiple dimensions: clinical specialisation (cardiac, oncology, orthopaedics, neurology), accreditation standards (NABH and JCI), Average Revenue Per Occupied Bed (ARPOB), and occupancy rates. Apollo and Max had built relatively clean institutional track records. Narayana Health had emerged as the cost-efficiency leader with strong clinical outcomes credentials. In this competitive field, Fortis entered 2018 as the most damaged brand — not from clinical failure, but from promoter-level governance collapse.

Brand Situation Prior to the Turnaround

The Promoter Fraud and Its Consequences

Fortis Healthcare was founded in 1996 by Malvinder Mohan Singh and Shivinder Mohan Singh as an offshoot of Ranbaxy Laboratories. By 2011, it had expanded into one of India's largest hospital chains, operating across multiple cities. However, the same year that the company reached its operational peak, the foundations of its ownership structure began to crack. In February 2018, the Singh brothers resigned from the board of Fortis Healthcare following allegations that they had siphoned approximately $78 million (roughly Rs 472–500 crore) from the publicly listed company — reportedly through inter-corporate deposits made to related entities without board approval. An external investigation confirmed that Malvinder Singh had authorised fund diversion to corporate bodies connected to the Singh family group. SEBI found these transactions to be "fraudulent" and directed the brothers to repay the amounts to Fortis. They failed to do so. The legal cascade deepened when Japanese drugmaker Daiichi Sankyo — which had acquired Ranbaxy from the Singh brothers in 2008 for approximately $4.6 billion — secured a Rs 3,500 crore arbitration award against the brothers from a Singapore tribunal in 2016 for concealing Ranbaxy's ongoing US FDA investigation during the sale. The Delhi High Court upheld this award in 2018. The brothers were ultimately arrested in October 2019 by the Economic Offences Wing of the Delhi Police on charges of financial fraud and causing a loss of Rs 2,397 crore to Religare Finvest. In 2022, the Supreme Court sentenced both brothers to six months' imprisonment for contempt.

The Brand Damage

The consequences for Fortis as a brand were severe and multidimensional. Public trust, already strained by media coverage of the fraud, was further eroded by news of legal proceedings involving the company's very founders. Vendor relationships suffered as financial uncertainty spread through the organisation. Internal morale deteriorated as employees confronted uncertainty about ownership, leadership, and continuity of operations. Occupancy dropped. The company reported a consolidated loss of Rs 934.42 crore on revenue of Rs 4,560.81 crore in FY2017-18. As Dr. Raghuvanshi later described the situation he inherited: "When we arrived, things were quite unstable. The hospital's credibility, vendor relationships, and public perception were largely negative, both with the press and patients... When I came aboard, the environment was one of fear and distrust."

The brand faced a textbook case of trust deficit in a credence-service market. Patients, partners, and investors had a rational basis for concern — not about the quality of clinical care per se, but about the institutional integrity of the entity providing it

.

Strategic Objective

Following IHH Healthcare's acquisition of a 31.1% controlling stake in Fortis through a preferential allotment of Rs 4,000 crore in November 2018, the strategic imperatives were clear: restore institutional confidence, stabilise operations, clean up governance, and rebuild a patient-centric brand identity untethered from the Singh-era legacy. The core brand objective was to separate Fortis's clinical identity and organisational credibility from its promoter history — essentially to reposition the brand from founder-associated to professionally managed, outcomes-driven, and transparently governed. This is a particularly difficult positioning challenge. In Indian healthcare, patients often associate hospital brands with founding families or prominent physicians. Severing that association while retaining the brand equity embedded in the Fortis name — and doing so under ongoing Supreme Court proceedings that kept the ownership structure in legal limbo — required a carefully layered strategy.

Strategic Architecture & Execution

Leadership Signal: The Raghuvanshi Appointment

IHH's first and most visible strategic signal was the appointment of Dr. Ashutosh Raghuvanshi as MD and CEO on 18 March 2019. A paediatric cardiac surgeon who had spent over 18 years at Narayana Health — including as its Vice Chairman, MD and Group CEO — Raghuvanshi was a credentialed clinician-administrator with a track record of building healthcare organisations grounded in operational efficiency and clinical outcomes. His appointment communicated three things simultaneously: a commitment to clinical leadership over financial engineering; a rupture from the prior ownership culture; and a connection to the Narayana Health model of value-based, patient-centric care.

IHH's stated mandate for the appointment, published through official corporate channels, reinforced this framing: "Dr Raghuvanshi's experience would be greatly valued in providing strategic direction and vision to the company and will ensure that our focus on clinical excellence, outcomes, patient centricity and business results remain paramount."

Governance and Board Restructuring

The IHH-installed board reflected a post-2018 governance reform model, with an independent-heavy composition, strengthened oversight committees, and the separation of the chairman and CEO roles — Non-Executive Chairman Ravi Rajagopal and MD & CEO Raghuvanshi operating in distinct capacities. This structure directly addressed the governance failure that had allowed the Singh-era fund diversions to proceed unchecked.

The company also initiated legal action to recover the Rs 500 crore allegedly siphoned by the former promoters — a public signal of institutional accountability rather than quiet cover-up.

Portfolio Rationalisation as Brand Signalling

Rather than aggressive network expansion — which would have stretched resources and distracted from quality control — the Raghuvanshi-led team adopted a deliberate portfolio rationalisation strategy. Fortis exited the Chennai market by selling its two loss-making facilities: Fortis Vadapalani to Sri Kauvery Medical Care in July 2023, and Fortis Malar to MGM Healthcare in February 2024. This willingness to divest underperforming assets communicated disciplined capital allocation and a focus on operational excellence over scale optics — both trust signals in a market where hospital chains had historically over-expanded. The company also undertook brownfield expansion at high-performing metro cluster hospitals (FMRI Gurugram, Shalimar Bagh Delhi, Bannerghatta Road Bengaluru, Noida, Mohali), rather than building new greenfield facilities. This cluster-density strategy allowed Fortis to deepen its clinical quality in markets where it already had patient relationships and reputation.

Clinical Credibility as the Core Brand Pillar

Recognising that in a credence service, the brand promise must be validated by observable clinical output rather than advertising, Fortis rebuilt its brand positioning around measurable clinical excellence. The company invested in accreditation — maintaining NABH and JCI certifications across its network. It invested in high-complexity specialties: oncology, cardiac sciences, neurology, nephrology, and robotic surgery. Da Vinci robotic systems were deployed across 18 facilities. LINACs, Cath Labs, and advanced neurological infrastructure were commissioned across key hospitals. In a significant and symbolically important transparency move, Fortis began reporting outcomes of cardiac procedures publicly on its website — a level of clinical disclosure unusual in Indian private healthcare and a direct institutional signal that it was willing to be held to measurable standards.

Digital Transformation as Patient Trust Infrastructure

Fortis's digital strategy served dual purposes: operational efficiency and patient trust-building through transparency and accessibility. The company launched an AI-powered virtual assistant on its website in May 2020 for digital triage — directly addressing patient anxiety during the COVID-19 period and demonstrating responsiveness. The myFortis app was developed to provide patients with access to health records, appointment booking, and medication reminders. Fortis also committed to a full Electronic Medical Records (EMR) system implementation across its network and undertook website revamp and ERP implementation as part of its digital transformation initiative, referenced in the FY 2023-24 Annual Report. Critically, digital channels accounted for approximately 25% of total revenues in Q3 FY24, rising to around 30% by Q2 FY26 — demonstrating that patient confidence in the digital interface had translated into measurable revenue flow. Digital channel revenues grew 33% year-over-year in Q4 FY24.

COVID-19 as a Trust-Rebuilding Moment

The pandemic, while operationally disruptive, provided Fortis a high-visibility opportunity to demonstrate patient-centric values under pressure. The company treated over 33,000 COVID-19 patients across its facilities. It reserved 1,600 beds for COVID-19 patients at the peak. It partnered with Common Services Centres (a Ministry of Electronics and IT SPV) for telemedicine delivery. Senior management and doctors voluntarily took pay cuts to protect frontline staff jobs. These decisions — documented in official communications and the Chairman's statement to shareholders in the FY 2020-21 Annual Report — generated institutional goodwill that advertising could not have purchased.

Medical Value Travel and International Positioning

Fortis's brand rebuilding included a meaningful push into medical value travel — international patients arriving for planned procedures. This segment, which signals quality credibility to domestic audiences (international patients conduct extensive pre-visit due diligence on clinical outcomes), grew from Rs 215 crore in FY 2021-22 to Rs 425 crore in FY 2022-23 — nearly doubling as a share of total revenues from 5% to 8.3%. By Q4 FY24, international patient revenues grew 9% year-over-year to Rs 124 crore in a single quarter, contributing approximately 8% to overall hospital business revenues.

Positioning & Consumer Insight

The underlying consumer insight driving Fortis's rebuilding strategy was both straightforward and strategically powerful: patients in Indian private healthcare are not merely buying a medical procedure — they are buying institutional safety in a context of vulnerability and information asymmetry. When an institution's founders are arrested for fraud, patients reasonably ask whether the same ethical framework applies to billing practices, clinical protocols, and procurement decisions affecting their care.

Fortis's trust-building strategy therefore operated not at the communications layer, but at the institutional layer. The brand did not attempt to "advertise" its way back to credibility. Instead, it deployed a sequence of institutional proof-points: credentialed leadership, governance reform, transparent clinical reporting, accreditation maintenance, and operational performance recovery. These are trust signals that patients and referring physicians can independently verify — which is precisely why they work in high-credence categories where advertising claims are discounted. The company's brand philosophy — articulated as "Saving Lives, Enriching Lives" — formalised this patient-centric positioning by combining a clinical promise with an experiential one. It addressed both the cognitive dimension of trust (clinical quality) and the emotional dimension (empathetic care), which is the full spectrum of what patients evaluate in a hospital relationship.

Media & Channel Strategy

No verified information is available on specific paid media spends, advertising campaign budgets, or detailed above-the-line media plans for the FY 2018–2024 period from official Fortis sources. What is documented from official and credible sources is that Fortis's channel strategy was weighted toward earned and owned channels rather than paid advertising. These included: digital channels (website, app, and campaigns) for patient acquisition; healthcare professional engagement and specialist recruitment to drive clinical referrals; corporate and insurance tie-ups to build institutional B2B credibility; community connect programs referenced by the Chairman in the FY 2020-21 Annual Report; and a medical value travel program for international patient acquisition. The company's content and SEO strategy, centred on a "Medical Wisdom" platform, generated significant organic search visibility in health-related categories.

Business & Brand Outcomes

The financial recovery is the most verifiable indicator of brand and operational restoration:

Revenue and Profitability Recovery: Fortis closed FY 2017-18 — the year of the promoter crisis — with a net loss of Rs 934.42 crore on revenue of Rs 4,560.81 crore. By FY 2022-23, the company reported a net profit of Rs 633 crore on total revenue of Rs 6,298 crore. For FY 2024-25, consolidated revenue from operations reached Rs 7,783 crore, compared to Rs 6,893 crore in FY 2023-24 — a year-on-year growth of approximately 13%.

ARPOB Improvement: ARPOB grew 10.3% in Q4 FY24 and 10.8% for the full year FY24. Hospital business revenues for FY 2024-25 stood at Rs 6,528 crore, an increase from Rs 5,686 crore in FY 2023-24 — growth driven specifically by a 9% year-on-year improvement in ARPOB.

Occupancy and Volume: Hospital occupancy reached 71% in Q2 FY26 (quarter ending September 2025), up from mid-60s levels in earlier recovery years.

Medical Value Travel: Revenue from medical travel grew from Rs 215 crore (FY 2021-22) to Rs 425 crore (FY 2022-23), representing a near-doubling. By Q2 FY26, medical travel revenue grew 26% year-on-year, contributing 8.1% to overall hospital revenues.

Digital Channel Growth: Revenue from digital channels contributed approximately 25% of total revenues in Q3 FY24, rising to approximately 30% by Q2 FY26. Digital channel revenues recorded 33% year-over-year growth in Q4 FY24.

Network Scale: The company operated 27 hospitals with over 4,500 operational beds as of 2024, rationalised from a larger but less profitable earlier network.

Debt Reduction: Net debt-to-EBITDA stood at 0.93x as of March 31, 2025 — a meaningful improvement reflecting improved cash generation and financial discipline.

Stock Performance: Fortis shares, which were at Rs 170 at the time of the IHH acquisition in 2018, had risen to approximately Rs 980 by October 2025 — though analyst reports from December 2023 noted the stock had still underperformed sector peers over the preceding three years, with a 3-year CAGR of approximately 37% compared to peers ranging from 43% to 122%.

Strategic Implications

Governance Reform as the Foundation of Brand Recovery In high-credence B2C categories — healthcare, financial services, education — brand trust cannot be rebuilt through communications alone. It requires structural reform at the institutional level. Fortis's most effective brand investment was not advertising; it was the appointment of credentialed leadership, the restructuring of its board with genuine independence, and the transparency of its legal and financial disclosures. Marketers operating in trust-deficit situations must recognise that the brand is an expression of the institution, not a layer applied on top of it.

Clinical Product as Brand Strategy The decision to invest in clinical specialisation — robotics, oncology, transplants, advanced cardiac care — while simultaneously improving accreditation and publishing outcomes data was a product-led brand strategy. In healthcare, a hospital's clinical outcomes ARE its brand equity. Fortis's ARPOB improvement was both a financial metric and a brand signal: higher ARPOB generally reflects a superior case-mix (more complex procedures), which in turn reflects physician confidence in referring patients, which is the most powerful proxy for clinical brand equity.

Portfolio Rationalisation Over Scale Expansion The willingness to exit loss-making facilities (Chennai) rather than defend network breadth was a strategically mature brand decision. Carrying underperforming assets dilutes clinical quality signals and creates internal management drag. By concentrating in high-performing metro clusters, Fortis made it possible to deliver consistent patient experience — the operational prerequisite for brand promise delivery.

The Role of Crisis in Brand Opportunity The COVID-19 pandemic created conditions under which Fortis could demonstrate institutional values in action. The organisation's pandemic response — bed reservations, patient education programs, telemedicine partnerships, salary sacrifices by leadership — generated authentic brand equity in a way that no campaign could have replicated. This underscores the principle that a brand's reputation is most powerfully shaped by how it behaves under pressure, not how it presents itself in normal conditions.

The Limits of Brand Recovery Under Legal Overhang Despite operational and financial recovery, Fortis shares continued to underperform sector peers through 2023, per analyst reports. This illustrates a critical constraint: even successfully executed brand rebuilding strategies can be discounted by capital markets if legal uncertainty persists. The Daiichi Sankyo litigation, the Supreme Court's stay on IHH's open offer, and the ongoing forensic audit proceedings created a "legal risk premium" that suppressed market valuation even as operating metrics improved. Brand equity and financial market valuation are related but not identical — a finding with implications for how companies manage stakeholder communication during legal proceedings.

Discussion Questions

Q1. Fortis chose to retain the Fortis brand name despite considering a rebrand to "Parkway" (IHH's Singapore brand). Using concepts of brand equity transfer, brand heritage, and brand risk, evaluate whether retaining the Fortis brand was the correct strategic decision. Under what conditions would a full rebrand have been preferable?

Q2. Fortis rebuilt brand trust primarily through institutional signals (governance, leadership, clinical accreditation) rather than consumer-facing advertising campaigns. Using the Service-Dominant Logic framework and the concept of brand as institutional promise, evaluate this approach. What are the risks of under-investing in demand-side brand communication during a recovery phase?

Q3. Dr. Raghuvanshi's background as a clinician-turned-administrator — rather than a traditional marketing or strategy executive — was central to IHH's leadership signalling strategy. How does leadership credentialing function as a brand asset in high-credence service categories? Draw parallels or contrasts with how other service industries (banking, education, consulting) use leadership identity in brand recovery.

Q4. Fortis's stock underperformed sector peers by a significant margin between 2020 and 2023, even as operating metrics improved steadily. How would you explain the gap between operational brand recovery and capital market valuation? What marketing and investor communications strategies could Fortis have employed to close this gap?

Q5. Analyse the medical value travel program's role in Fortis's brand strategy. Beyond revenue contribution, what is the strategic signalling value of international patient volume for a domestic healthcare brand attempting to recover institutional credibility? How does this intersect with Mental Availability theory in a market where patients have high purchase anxiety?